PCSK9 and familial hyperaldosteronism: Thus, the beneficial effect of PCSK9-i on the functional lipid profile could contribute to restore the normal lipoprotein functions and eventually to the CV benefit of these drugs beyond LDL cholesterol (LDL-c) reduction in high CV risk subjects such as FH.